Next generation sequencing of HIV-1 protease in the PIVOT trial of protease inhibitor monotherapy

The UK-based PIVOT trial examined whether patients with suppressed viral load (VL) on combination antiretroviral therapy could be safely switched to ritonavir-boosted protease inhibitor (PI) monotherapy, with regular HIV VL monitoring and prompt reintroduction of combination therapy for VL rebound (defined as a confirmed VL ≥50 copies/ml) [1]. The primary outcome in the trial was the loss of future drug options, defined as intermediate to high level resistance (predicted from genotype) to one or more licensed drugs in contemporary use.

Source: Journal of Clinical Virology - February 5, 2018 Category: Virology Authors: David T. Dunn, Wolfgang St öhr, Alejandro Arenas-Pinto, Anna Tostevin, Jean L. Mbisa, Nicholas I. Paton, for the Protease Inhibitor Monotherapy Versus Ongoing Triple Therapy PIVOT Trial Team Tags: Short communication Source Type: research